SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report:

March 26, 2010

CSMG TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Charter)

Texas		0-27359		74-2653437
(State of Incorporation)		(Commission File Number )		(IRS Employer Identification No.)

1005 North Tower, 500 North Shoreline Drive

Corpus Christi, TX 78471

(Address of principal executive offices) (Zip Code)

361-884-6118

(Registrant's telephone number)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On March 26, 2010 the Registrant (“CSMG”) issued a press release regarding the new management team that has been engaged to lead its subsidiary, Live Tissue Connect, Inc., in its efforts to commercialize the tissue bonding technology. A copy of the press release is attached as an exhibit to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated March 26, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	CSMG Technologies, Inc.

Date: March 26, 2010	By:	/s/ Dr. Joseph Kutz
		Dr. Joseph Kutz
		President and Chief Executive Officer

CSMG TECHNOLOGIES, INC. 8-K